The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.
대표청구항▼
1. A method for reducing a fat deposit in an individual, the method comprising administering to the fat deposit a compound selected from the group consisting of: bimatoprost, latanoprost, travoprost, and pharmaceutically acceptable salts thereof; wherein the individual suffers from a condition chara
1. A method for reducing a fat deposit in an individual, the method comprising administering to the fat deposit a compound selected from the group consisting of: bimatoprost, latanoprost, travoprost, and pharmaceutically acceptable salts thereof; wherein the individual suffers from a condition characterized at least in part by an undesired fat deposit. 2. The method of claim 1, wherein the condition is a cosmetic condition. 3. The method of claim 1, wherein the condition is a medical condition. 4. The method of claim 1, wherein the compound is bimatoprost. 5. The method of claim 1, wherein the compound is latanoprost. 6. The method of claim 1, wherein the compound is travoprost. 7. The method of claim 1, wherein the administering is by topical application. 8. The method of claim 1, wherein the administering is by injection. 9. The method of claim 1, wherein the administering is by implantation. 10. The method of claim 1, wherein the deposit is on the face. 11. The method of claim 1, wherein the deposit is on the chin. 12. The method of claim 1, wherein the deposit is on the neck. 13. The method of claim 1, wherein the deposit is on the arms. 14. The method of claim 1, wherein the deposit is orbital fat. 15. The method of claim 1, wherein the deposit is a lipoma. 16. The method of claim 1, wherein the compound is provided in a pharmaceutical composition, wherein the concentration of the compound is between about 0.003% and about 0.3%, inclusive. 17. The method of claim 1, wherein the compound is provided in a pharmaceutical composition, wherein the concentration of the compound is between about 0.03% and about 0.3%, inclusive. 18. The method of claim 1, wherein the compound is provided in a solution. 19. The method of claim 1, wherein the compound is provided in a sustained-release formulation. 20. The method of claim 1, wherein the is provided in an implantable depot.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (58)
Ling, Kah-Hiing John; Yang, Wu; Ni, Jinsong; Yuan, Haiqing; Tang-Liu, Diane D. S., 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Woodward David F. (El Toro CA) Andrews Steven W. (Rancho Santa Marguerita CA) Burk Robert M. (Irvine CA) Garst Michael E. (Newport Beach CA), Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Pintor, Jesus J.; Peral, Maria A.; Peterson, Ward M.; Plourde, Jr., Robert; Brown, Edward G.; Yerxa, Benjamin R., Method for reducing intraocular pressure using indole derivatives.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
David F. Woodward ; Steven W. Andrews ; Robert M. Burk ; Michael E. Garst, Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents.
Klimko Peter G. ; Bishop John E. ; Sallee Verney L. ; Zinke Paul W., Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension.
Hellberg, Mark R.; Nixon, Jon C., Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.